JP2015537017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015537017A5 JP2015537017A5 JP2015542259A JP2015542259A JP2015537017A5 JP 2015537017 A5 JP2015537017 A5 JP 2015537017A5 JP 2015542259 A JP2015542259 A JP 2015542259A JP 2015542259 A JP2015542259 A JP 2015542259A JP 2015537017 A5 JP2015537017 A5 JP 2015537017A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- alkyl
- tumors
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 35
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 230000024932 T cell mediated immunity Effects 0.000 claims 9
- 230000010261 cell growth Effects 0.000 claims 9
- 230000004663 cell proliferation Effects 0.000 claims 9
- 230000001413 cellular effect Effects 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 230000028709 inflammatory response Effects 0.000 claims 9
- 230000004083 survival effect Effects 0.000 claims 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 206010027476 Metastases Diseases 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 3
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 206010029098 Neoplasm skin Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 230000029087 digestion Effects 0.000 claims 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000037841 lung tumor Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 201000004477 skin sarcoma Diseases 0.000 claims 3
- 210000003932 urinary bladder Anatomy 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 2
- IUXLKJIIJFOHGT-GDBMZVCRSA-N (1r,2r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexan-1-ol Chemical compound O[C@@H]1CCCC[C@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 IUXLKJIIJFOHGT-GDBMZVCRSA-N 0.000 claims 1
- SHCMXGVWKMGYLQ-UKRRQHHQSA-N (1r,2r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclopentan-1-ol Chemical compound O[C@@H]1CCC[C@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 SHCMXGVWKMGYLQ-UKRRQHHQSA-N 0.000 claims 1
- IUXLKJIIJFOHGT-GOEBONIOSA-N (1r,2s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexan-1-ol Chemical compound O[C@@H]1CCCC[C@@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 IUXLKJIIJFOHGT-GOEBONIOSA-N 0.000 claims 1
- SHCMXGVWKMGYLQ-DZGCQCFKSA-N (1r,2s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclopentan-1-ol Chemical compound O[C@@H]1CCC[C@@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 SHCMXGVWKMGYLQ-DZGCQCFKSA-N 0.000 claims 1
- SHCMXGVWKMGYLQ-HIFRSBDPSA-N (1s,2r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclopentan-1-ol Chemical compound O[C@H]1CCC[C@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 SHCMXGVWKMGYLQ-HIFRSBDPSA-N 0.000 claims 1
- IUXLKJIIJFOHGT-HOCLYGCPSA-N (1s,2s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexan-1-ol Chemical compound O[C@H]1CCCC[C@@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 IUXLKJIIJFOHGT-HOCLYGCPSA-N 0.000 claims 1
- SHCMXGVWKMGYLQ-ZFWWWQNUSA-N (1s,2s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclopentan-1-ol Chemical compound O[C@H]1CCC[C@@H]1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 SHCMXGVWKMGYLQ-ZFWWWQNUSA-N 0.000 claims 1
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 1
- UDCLRMQFJSADBD-UHFFFAOYSA-N 3-[(3-furo[3,2-c]pyridin-2-ylimidazo[1,2-b]pyridazin-6-yl)amino]cyclobutan-1-ol Chemical compound C1C(O)CC1NC1=NN2C(C=3OC4=CC=NC=C4C=3)=CN=C2C=C1 UDCLRMQFJSADBD-UHFFFAOYSA-N 0.000 claims 1
- SEJFYYQJWNNTMG-UHFFFAOYSA-N 4-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 SEJFYYQJWNNTMG-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- YYDHMEFBZRCSKG-MQMHXKEQSA-N O[C@H]1C[C@H](CNc2ccc3ncc(-c4cc5ccccc5o4)n3n2)C1 Chemical compound O[C@H]1C[C@H](CNc2ccc3ncc(-c4cc5ccccc5o4)n3n2)C1 YYDHMEFBZRCSKG-MQMHXKEQSA-N 0.000 claims 1
- ATINSVAPEYBCJL-UHFFFAOYSA-N [3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]cyclobutyl]methanol Chemical compound C1C(CO)CC1NC1=NN2C(C=3OC4=CC=CC=C4C=3)=CN=C2C=C1 ATINSVAPEYBCJL-UHFFFAOYSA-N 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- -1 compound Salt Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 0 *c1cc(ccnc2)c2[o]1 Chemical compound *c1cc(ccnc2)c2[o]1 0.000 description 2
- LLATZLXZFAVJHD-UHFFFAOYSA-N NC(C1)Oc2c1nccc2 Chemical compound NC(C1)Oc2c1nccc2 LLATZLXZFAVJHD-UHFFFAOYSA-N 0.000 description 1
- HFZZTHJMXZSGFP-UHFFFAOYSA-N Nc1cc2ccccc2[o]1 Chemical compound Nc1cc2ccccc2[o]1 HFZZTHJMXZSGFP-UHFFFAOYSA-N 0.000 description 1
- YICQOHVMRMLJFF-UHFFFAOYSA-N Nc1cc2cnccc2[o]1 Chemical compound Nc1cc2cnccc2[o]1 YICQOHVMRMLJFF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12193192 | 2012-11-19 | ||
| EP12193192.7 | 2012-11-19 | ||
| PCT/EP2013/073793 WO2014076162A1 (en) | 2012-11-19 | 2013-11-14 | Aminoimidazopyridazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015537017A JP2015537017A (ja) | 2015-12-24 |
| JP2015537017A5 true JP2015537017A5 (enExample) | 2016-12-28 |
Family
ID=47177840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542259A Ceased JP2015537017A (ja) | 2012-11-19 | 2013-11-14 | アミノイミダゾピリダジン類 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9783543B2 (enExample) |
| EP (1) | EP2920176B1 (enExample) |
| JP (1) | JP2015537017A (enExample) |
| CN (1) | CN104797585B (enExample) |
| CA (1) | CA2891644A1 (enExample) |
| ES (1) | ES2646916T3 (enExample) |
| HK (1) | HK1208025A1 (enExample) |
| WO (1) | WO2014076162A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012163942A1 (en) | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JP6147761B2 (ja) | 2011-12-12 | 2017-06-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | アミノ置換イミダゾピリダジン |
| CA2868673A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| CN104321326B (zh) | 2012-04-04 | 2017-05-31 | 拜耳医药股份有限公司 | 氨基取代的咪唑并哒嗪 |
| WO2014076162A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| AU2014207691B2 (en) | 2013-01-15 | 2018-08-30 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| EP2951181A1 (en) | 2013-01-30 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| CN105899512A (zh) | 2014-01-09 | 2016-08-24 | 拜耳医药股份公司 | 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| DK3285809T3 (da) | 2015-04-20 | 2019-11-18 | Effector Therapeutics Inc | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN105548420B (zh) * | 2015-12-30 | 2019-08-02 | 上海泽润生物科技有限公司 | Mops残留量的检测方法 |
| EP3397774A1 (en) | 2015-12-31 | 2018-11-07 | Effector Therapeutics Inc. | Mnk biomarkers and uses thereof |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4408047A (en) | 1980-03-28 | 1983-10-04 | Merck & Co., Inc. | Imidazodiazines |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| FR2619818B1 (fr) | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO2003018020A1 (en) | 2001-08-23 | 2003-03-06 | Takeda Chemical Industries, Ltd. | Jnk inhibitors |
| JP2009502734A (ja) * | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2007033080A2 (en) | 2005-09-12 | 2007-03-22 | Emory University | Alzheimer's disease imaging agents |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| RU2009101911A (ru) | 2006-06-22 | 2010-07-27 | Биовитрум Аб (Пабл) (Se) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| NZ576234A (en) | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| CA2710458A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| CA2836203A1 (en) | 2011-05-17 | 2012-11-22 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| WO2012163942A1 (en) * | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| HK1197063A1 (en) * | 2011-06-22 | 2015-01-02 | 拜耳知识产权有限责任公司 | Heterocyclyl aminoimidazopyridazines |
| AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| JP6174586B2 (ja) | 2011-09-23 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| JP6147761B2 (ja) * | 2011-12-12 | 2017-06-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | アミノ置換イミダゾピリダジン |
| CA2868673A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| CN104321326B (zh) | 2012-04-04 | 2017-05-31 | 拜耳医药股份有限公司 | 氨基取代的咪唑并哒嗪 |
| WO2014076162A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| EP2951181A1 (en) | 2013-01-30 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| HK1212699A1 (zh) | 2013-02-20 | 2016-06-17 | 拜耳医药股份公司 | 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物 |
| CN105899512A (zh) | 2014-01-09 | 2016-08-24 | 拜耳医药股份公司 | 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪 |
-
2013
- 2013-11-14 WO PCT/EP2013/073793 patent/WO2014076162A1/en not_active Ceased
- 2013-11-14 CA CA2891644A patent/CA2891644A1/en not_active Abandoned
- 2013-11-14 ES ES13795702.3T patent/ES2646916T3/es active Active
- 2013-11-14 CN CN201380060430.6A patent/CN104797585B/zh not_active Expired - Fee Related
- 2013-11-14 HK HK15108632.0A patent/HK1208025A1/xx unknown
- 2013-11-14 EP EP13795702.3A patent/EP2920176B1/en not_active Not-in-force
- 2013-11-14 JP JP2015542259A patent/JP2015537017A/ja not_active Ceased
- 2013-11-14 US US14/443,688 patent/US9783543B2/en not_active Expired - Fee Related